Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2-Reference-Cited by-同舟云学术

Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2

Published:2016-01-19 Issue:3 Volume:8 Page:604-616
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Siebert Nikolai,Eger Christin,Seidel Diana,Jüttner Madlen,Zumpe Maxi,Wegner Danilo,Kietz Silke,Ehlert Karoline,Veal Gareth J.,Siegmund Werner,Weiss Michael,Loibner Hans,Ladenstein Ruth,Lode Holger N.

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/19420862.2015.1130196

Reference18 articles.

1. The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

2. Disialoganglioside Directed Immunotherapy of Neuroblastoma

3. Anti-GD2 strategy in the treatment of neuroblastoma

4. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

5. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuroblastoma: an ongoing cold front for cancer immunotherapy;Journal for ImmunoTherapy of Cancer;2023-11

2. Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study;British Journal of Cancer;2023-10-10

3. Safety and efficacy of dinutuximab in the treatment of neuroblastoma: A review;Journal of Research in Medical Sciences;2023-09

4. Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta;Cancers;2023-06-23

5. Pain mitigation and management strategies for anti‐GD2 infusions: An expert consensus;Pediatric Blood & Cancer;2023-02-11